November 2018
Sequentia Biotech creates the spin-out Biotech Tricopharming Research to market Artennua, its first biopharmaceutical agriculture product.
Sequentia spin-out Biotech Tricopharming Research is constituted to commercialize Artennua
Sequentia Biotech has created Biotech Tricopharming Research as a spin-out to commercialise Artennua, an optimized version of Artemisia annua, and the first product to derive from their agropharma R&D department. Sequentia was able to quintuplicate the annual production of the plant, triplicate the foliar biomass and duplicate the concentration of artemisinin in the lab. This…
